Sanofi to acquire Dren Bio's immunology unit

, Reuters -  2:37 AM ET 3/20/2025 mergers-and-acquisitions

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

(Reuters) - Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.

The French healthcare group will acquire the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totalling $1.3 billion, it said in a statement.

The transaction is expected to close in the second quarter of 2025, it added.

(Reporting by Alban Kacher)

(c) Reuters 2025. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.